DexCom earnings beat by $0.03, revenue topped estimates
Investing.com -- Shares of Medacta surged 7% following the release of its fully audited second-half results, which revealed adjusted EBITDA and net income figures surpassing consensus estimates. The company’s guidance remained consistent with current consensus revenue and adjusted EBITDA forecasts.
Medacta’s financial performance showcased resilience, with the second-half adjusted EBITDA coming in 8% ahead of consensus expectations, implying a margin of 27.4% compared to the anticipated 25.6%. This margin expansion was attributed to the company’s ability to scale and improve productivity.
Moreover, reported net income for the same period was 15% higher than consensus, at EUR 35 million versus the expected EUR 31 million, bolstered by favorable foreign exchange gains and improved net financial costs.
While gross profit aligned with consensus, indicating a margin of 66.8%, it represented a slight decline from the second half of the previous year due to adverse FX effects. However, the company demonstrated significant operational efficiency with cash from operations climbing to EUR 107 million, a substantial increase from EUR 75 million in the prior year, supported by improved inventory management.
Capital expenditures were approximately EUR 105 million, with over 80% allocated to growth capex and instrumentation, signaling Medacta’s continued investment in expansion.
Looking forward, Medacta’s management has provided guidance for revenue growth of 13-15% in constant currency and an adjusted EBITDA margin of 27%. This outlook suggests stability in consensus revenue and adjusted EBITDA expectations at the midpoint.
UBS analysts commented on the results, stating, "The strong margin performance in H2 and cash delivery should reassure investors that top-line growth is not coming at the expense of profitability. Added to this, the guidance underpins current consensus and management has had a good track record of beating and raising sales guidance in particular."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.